Pharmacy Department, Kaiser Permanente Colorado, 16601 E. Centretech Pkwy., Aurora, CO 80011, USA.
Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):673-80. doi: 10.1158/1055-9965.EPI-11-1075. Epub 2012 Feb 15.
Cancer Research Network (CRN) sites use administrative data to populate their Virtual Data Warehouse (VDW). However, information on VDW chemotherapy data validity is limited. The purpose of this study was to assess the validity of VDW chemotherapy data.
This was a retrospective cohort study of women ≥18 years with incident, invasive breast cancer diagnosed between January 1999 and December 2007. Pharmacy and procedure chemotherapy data were extracted from each site's VDW. Random samples of 50 patients stratified on trastuzumab, anthracyclines, and no chemotherapy exposure was selected from each site for detailed chart abstraction. Weighted sensitivities and specificities of VDW compared with abstracted data were calculated. Cumulative doses calculated from VDW data were compared with doses obtained from the medical chart review.
The cohort included 13,497 patients with 6,456 (48%) chart review eligible. Patients in the sample (N = 400) had a mean age of 65 years. Trastuzumab, anthracycline, and other chemotherapy weighted sensitivities were 95%, 97%, and 100%, respectively; specificities were 99%, 99%, and 93%, respectively; positive predictive values were 96%, 99%, and 55%, respectively; and negative predictive values were 99%, 96%, and 100%. Trastuzumab and anthracyclines VDW mean doses were 873 and 386 mg, respectively, whereas abstracted mean doses were 1,734 and 369 mgs, respectively (R(2) = 0.14, P < 0.01 and R(2) = 0.05, P = 0.03, respectively).
Sensitivities and specificities for CRN chemotherapy VDW data were high and dosages were correlated with chart information.
The findings support the use of CRN data in evaluating chemotherapy exposures and related outcomes.
癌症研究网络（CRN）站点使用行政数据来填充其虚拟数据仓库（VDW）。然而，关于 VDW 化疗数据有效性的信息有限。本研究的目的是评估 VDW 化疗数据的有效性。
这是一项回顾性队列研究，纳入 1999 年 1 月至 2007 年 12 月期间诊断为浸润性乳腺癌的年龄≥18 岁的女性患者。从每个站点的 VDW 中提取药房和程序化疗数据。从每个站点中按曲妥珠单抗、蒽环类药物和无化疗暴露分层选择 50 名患者的随机样本进行详细的图表提取。计算 VDW 与提取数据相比的加权敏感度和特异性。从 VDW 数据计算的累积剂量与从医疗图表审查获得的剂量进行比较。
该队列包括 13497 名患者，其中 6456 名（48%）符合图表审查条件。样本（N=400）患者的平均年龄为 65 岁。曲妥珠单抗、蒽环类药物和其他化疗的加权敏感度分别为 95%、97%和 100%；特异性分别为 99%、99%和 93%；阳性预测值分别为 96%、99%和 55%；阴性预测值分别为 99%、96%和 100%。曲妥珠单抗和蒽环类药物 VDW 的平均剂量分别为 873 和 386mg，而提取的平均剂量分别为 1734 和 369mg（R²=0.14，P<0.01 和 R²=0.05，P=0.03）。
CRN 化疗 VDW 数据的敏感度和特异性较高，剂量与图表信息相关。
这些发现支持使用 CRN 数据评估化疗暴露和相关结局。
